Literature DB >> 14635022

Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model.

Shawn Babiuk1, Danuta M Skowronski, Gaston De Serres, Kent HayGlass, Robert C Brunham, Lorne Babiuk.   

Abstract

During the 2000-2001 season, a newly identified oculo-respiratory syndrome (ORS) was detected across Canada as an adverse effect to one influenza vaccine. The implicated vaccine contained a higher than expected proportion of unsplit and aggregated influenza virions. Clinical and epidemiologic features of ORS were suggestive of type 2-like influences on the immune response. We hypothesized that the implicated vaccine from the 2000-2001 season would induce greater Th2-like polarization relative to the non-implicated vaccine from the same season. Three groups consisting of eight mice each were either immunized with implicated vaccine, immunized with non-implicated vaccine or not immunized. Antigen-specific cellular responses were characterized based on the balance of Th2 (IL-4, IL-5) and Th1 (IFN-gamma) cytokines in vitro. We confirm that vaccine aggregates deviate the immune response to a greater Th2 cytokine pattern with potential implications for vaccine screening, safety, and efficacy. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14635022     DOI: 10.1002/jmv.10540

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

1.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

3.  Flexibility accompanies commitment of memory CD4 lymphocytes derived from IL-4 locus-activated precursors.

Authors:  Eric Adeeku; Prathyusha Gudapati; Yanice Mendez-Fernandez; Luc Van Kaer; Mark Boothby
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-30       Impact factor: 11.205

4.  Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice.

Authors:  Elinor Willis; Norbert Pardi; Kaela Parkhouse; Barbara L Mui; Ying K Tam; Drew Weissman; Scott E Hensley
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 17.956

5.  Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration.

Authors:  Merry Christie; Raul M Torres; Ross M Kedl; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

Review 6.  The weight of obesity on the human immune response to vaccination.

Authors:  Scott D Painter; Inna G Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2015-07-08       Impact factor: 3.641

7.  Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.

Authors:  Jae-Min Song; Yeu-Chun Kim; Aleksandr S Lipatov; Marc Pearton; C Todd Davis; Dae-Goon Yoo; Kyoung-Mi Park; Li-Mei Chen; Fu-Shi Quan; James C Birchall; Ruben O Donis; Mark R Prausnitz; Richard W Compans; Sang-Moo Kang
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

Review 8.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 9.  HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee.

Authors:  Chantal Sauvageau; Christine Dufour-Turbis
Journal:  Hum Vaccin Immunother       Date:  2015-11-10       Impact factor: 3.452

10.  Development of a bio-analytical strategy for characterization of vaccine particles combining SEC and nanoES GEMMA.

Authors:  Marlene Havlik; Martina Marchetti-Deschmann; Gernot Friedbacher; Paul Messner; Wolfgang Winkler; Laura Perez-Burgos; Christa Tauer; Günter Allmaier
Journal:  Analyst       Date:  2014-03-21       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.